Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-030 vs Vectibix in First-line mCRC
NCT07543744Phase 1Recruiting
- Sponsor
- R-Pharm
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of panitumumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by R-Pharm. Primary endpoints: Area under the concentration-time curve from time 0 to 336 hours and Area under the concentration-time curve at steady state. Started Apr 2025; status: recruiting.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07543744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543744.